LOGIN  |  REGISTER
Terns Pharmaceuticals
Recursion

NeueHealth to Host Second Quarter 2024 Earnings Conference Call on August 7, 2024

July 18, 2024 | Last Trade: US$7.29 2.98 69.14

DORAL, Fla. / Jul 18, 2024 / Business Wire / NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE), the value-driven healthcare company, today announced it will report Second Quarter financial results before the financial markets open on Wednesday, August 7, 2024, followed by a conference call at 8:00 AM Eastern Time.

To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call.

A webcast of the earnings call may also be accessed via NeueHealth’s Investor Relations page at investors.neuehealth.com. The company suggests participants for the conference call dial in at least 15 minutes in advance of the call. A recording of the earnings call and presentation will be available on NeueHealth’s Investor Relations page following the call.

About NeueHealth

NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 500,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare ecosystem. For more information, visit: www.neuehealth.com.

Chimerix

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB